| Sign In to gain access to subscriptions and/or personal tools. |
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosusArthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA, jamesj{at}omrf.ouhsc.edu, Departments of Medicine and Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA
Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA, Genetic Epidemiology Unit, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA, Departments of Medicine and Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA
Broegelmann Research Laboratory, University of Bergen, Norway
Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
Departments of Rheumatology, Walter Reed Army Medical Center Washington, DC 20307, USA
Departments of Rheumatology, Walter Reed Army Medical Center Washington, DC 20307, USA, National Institute of Arthritis, Musculoskeletal and Skin Disease, Bethesda, MD 20892, USA
Clinical Pharmacology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA, Departments of Medicine and Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA, U.S. Department of Veterans Affairs, Oklahoma City, OK 73104, USA Systemic lupus erythematosus (SLE) is a clinically diverse, complex autoimmune disease which may present with coincident onset of many criteria or slow, gradual symptom accrual. Early intervention has been postulated to delay or prevent the development of more serious sequelae. One option for treatment in this setting is hydroxychloroquine. Using 130 US military personnel who later met ACR SLE criteria, a retrospective study of onset, development and progression of SLE with and without pre-classification hydroxychloroquine (n = 26) use was performed. Patients treated with hydroxychloroquine prior to diagnosis had a longer (Wilcoxon signed rank test, P = 0.018) time between the onset of the first clinical symptom and SLE classification (median: 1.08 versus 0.29 years). Patients treated with prednisone before diagnosis also more slowly satisfied the classification criteria (Wilcoxon signed rank test, P = 0.011). The difference in median times between patients who received NSAIDs before diagnosis, as opposed to those who did not, was not different (P = 0.19). Patients treated with hydroxychloroquine also had a lower rate of autoantibody accumulation and a decreased number of autoantibody specificities at and after diagnosis. These findings are consistent with early hydroxychloroquine use being associated with delayed SLE onset. A prospective, blinded trial testing the capacity of hydroxychloroquine to delay or prevent SLE in high risk populations is warranted. Lupus (2007) 16, 401—409.
Key Words: hydroxychloroquine • SLE • systemic lupus erythematosus • therapy
Lupus, Vol. 16, No. 6,
401-409 (2007) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
